

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Hawkesworth, S; Moore, SE; Fulford, AJ; Barclay, GR; Darboe, AA; Mark, H; Nyan, OA; Prentice, AM (2013) Evidence for metabolic endotoxemia in obese and diabetic Gambian women. *Nutrition & diabetes*, 3. e83. ISSN 2044-4052 DOI: <https://doi.org/10.1038/nutd.2013.24>

Downloaded from: <http://researchonline.lshtm.ac.uk/1179135/>

DOI: [10.1038/nutd.2013.24](https://doi.org/10.1038/nutd.2013.24)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

ORIGINAL ARTICLE

Evidence for metabolic endotoxemia in obese and diabetic Gambian women

S Hawkesworth¹, SE Moore^{1,2}, AJC Fulford^{1,2}, GR Barclay³, AA Darboe², H Mark², OA Nyan⁴ and AM Prentice^{1,2}

OBJECTIVE: Emerging evidence from animal models suggests that translocation of bacterial debris across a leaky gut may trigger low-grade inflammation, which in turn drives insulin resistance. The current study set out to investigate this phenomenon, termed 'metabolic endotoxemia', in Gambian women.

METHODS: In a cross-sectional study, we recruited 93 age-matched middle-aged urban Gambian women into three groups: lean (body mass index (BMI): 18.5–22.9 kg m⁻²), obese non-diabetic (BMI: ≥30.0 kg m⁻²) and obese diabetic (BMI: ≥30.0 kg m⁻² and attending a diabetic clinic). We measured serum bacterial lipopolysaccharide (LPS) and endotoxin-core IgM and IgG antibodies (EndoCAb) as measures of endotoxin exposure and interleukin-6 (IL-6) as a marker of inflammation.

RESULTS: Inflammation (IL-6) was independently and positively associated with both obesity and diabetes ($F = 12.7, P < 0.001$). LPS levels were highest in the obese-diabetic group compared with the other two groups ($F = 4.4, P < 0.02$). IgM EndoCAb (but not total IgM) was highly significantly reduced in the obese (55% of lean value) and obese diabetic women (30% of lean; $F = 21.7, P < 0.0001$ for trend) compared with lean women.

CONCLUSION: These data support the hypothesis that gut-derived inflammatory products are associated with obesity and diabetes. Confirmation of these findings and elucidation of the role of the microbiota, gut damage and the pathways for translocation of bacterial debris, could open new avenues for prevention and treatment of type 2 diabetes.

Nutrition & Diabetes (2013) 3, e83; doi:10.1038/nutd.2013.24; published online 26 August 2013

Keywords: type 2 diabetes; bacteria; metabolic endotoxemia; The Gambia

INTRODUCTION

Although obesity is the leading risk factor for metabolic syndrome, insulin resistance and type 2 diabetes, not all obese individuals go on to develop disease.¹ Type 2 diabetes is a heterogeneous condition with aetiologies reflecting a complex interaction between genes and environment, including diet, physical activity and factors operating in early life. Among these exposures, low-grade inflammation (assessed by a range of markers including C-reactive protein, sialic acid, tumour necrosis factor (TNF) and interleukin-6 (IL-6)) has emerged as a consistent correlate of metabolic syndrome^{2–4} and a strong predictor of progression to incident type 2 diabetes among at-risk individuals.^{5,6} Macrophage infiltration of adipose tissue, driven by adipocyte-secreted macrophage chemoattractant protein-1, has hitherto been considered the most likely source of such inflammation and could explain the correlations with adipose tissue mass.⁷ However, recent research suggests an alternate or additional explanation by which bacterial products are translocated across the gut, either in association with a high-fat diet or due to gut damage, and thereby drive the inflammation, so-called 'metabolic endotoxemia' (ME).^{8–10}

Animal and human data have suggested that the composition of the gut microflora may be an important mediator of the risk of obesity and diabetes.^{10,11} Germ-free mice are protected against the metabolic complications of exposure to a high-fat/high-refined sugar 'Western' diet¹² and the transplantation of gut

microbiota from obese animals results in adiposity in those who are born germ-free.¹³ One suggested mechanism is through a more efficient energy harvest.¹⁴ Additional evidence suggests that the microbiota can influence metabolic disease through a separate mechanism. Bacterial lipopolysaccharide (LPS, also termed endotoxin) is released from dead Gram-negative bacteria in the gut and under conditions of gut damage can translocate into the circulation (as can whole bacteria) where it triggers an inflammatory response.¹⁵ Using mouse models, Cani and colleagues have demonstrated that exposure to a high-fat diet increases systemic endotoxin concentration, a phenomenon they termed 'ME' in recognition of the fact that levels are much lower than those observed in septic shock.⁹ In addition, mice infused with similarly low levels of LPS demonstrate raised glucose mimicking the levels observed for mice fed a high-fat diet.⁹

Few studies have investigated the association between endotoxemia and obesity in humans. A study in Saudi Arabian patients reported a positive association between endotoxin levels and various components of the metabolic syndrome,¹⁶ whereas another study in healthy French men reported a positive association between energy intake and endotoxemia.¹⁷

The inner-core of LPS molecules is relatively conserved across species and antibodies to this are therefore the most cross-reactive.¹⁸ Anti-endotoxin core antibodies (EndoCAb)¹⁹ may provide information on longer-term endotoxin exposure and have not yet been studied in the context of obesity

¹Medical Research Council International Nutrition Group, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK; ²Medical Research Council International Nutrition Group, MRC Keneba, The Gambia; ³SNBTS Cell Therapy Research Group, Centre for Regenerative Medicine, University of Edinburgh, Scotland, UK and ⁴School of Medicine and Allied Health Sciences, University of Gambia, Banjul, The Gambia. Correspondence: Dr S Hawkesworth, Epidemiology and Population Health, Medical Research Council International Nutrition Group, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

E-mail: sophie.hawkesworth@lshtm.ac.uk

Received 28 May 2013; accepted 11 July 2013

and diabetes. Here we present data on the cross-sectional association between diabetes and endotoxemia in urban-dwelling lean, obese and obese diabetic Gambian women.

SUBJECTS AND METHODS

Three groups of women were recruited into the study from the urban Bakau district of the Gambia, West Africa. We selected a lean (body mass index (BMI): 18.5–22.9 kg m⁻²) and obese (BMI >30 kg m⁻²) group from the general population using convenience sampling by screening households in the area and matching recruited women for age. A third group of obese women with diagnosed type 2 diabetes mellitus were recruited from the diabetic clinic at the Royal Victoria Teaching Hospital in the Gambian capital of Banjul. The study protocol was approved by the Scientific Coordinating Committee of Medical Research Council (MRC) Unit, the Gambia, and ethics permission was granted by the joint Gambian Government/MRC Ethics Committee. Full informed consent was obtained from each participant before enrolment into the study.

Participants were invited to attend a study morning at MRC Fajara in a fasted state. Weight was measured to the nearest 0.1 kg using daily calibrated, digital scales (Tanita Corporation, Tokyo, Japan). Height was measured using a daily calibrated stadiometer (Leicester height measure, Seca 214, Birmingham, UK) to the nearest 0.1 cm and BMI was defined as weight(kg)/height(m)². Body composition was further assessed by bioelectrical impedance analysis using the Tanita BC-418MA (Tanita Corporation) segmental analyser. Blood pressure was measured in triplicate using the automated Omron 705IT device (Omron, Kyoto, Japan) and following the manufacturer's instructions. Stool and fasted blood samples were collected, processed and frozen at -80 °C for analysis at a later date. Women were also interviewed during the study visit and data were recorded on their level of education and various assets owned by their household.

Insulin was measured using the AxSYM Microparticle Enzyme Immunoassay (Abbott Laboratories, North Chicago, IL, USA) with a detection limit of 1.0 µU insulin per ml. Glucose was measured on the VITROS 5600 Integrated System (Ortho-Clinical Diagnostics, Rochester, NY, USA) using the slide method with a detection range of 1.11–34.69 mmol l⁻¹. Plasma IL-6 was measured using the eBioscience IL-6 high-sensitivity ELISA with a detection limit of 0.03 pg ml⁻¹ (Bender MedSystems, Vienna, Austria; intra-assay CV: 4.9%). Faecal calprotectin was measured using the CALPRO Calprotectin ELISA Test (ALP) with a detection limit of 6.25 ng ml⁻¹ (Firefly Scientific, Manchester, UK; intra-assay CV: 1.9%). Calprotectin was assayed because faecal levels have been shown to correlate with the number of polymorphonuclear granulocytes entering the gut lumen.²⁰ Serum endotoxin concentrations were measured using the Endpoint Chromogenic Limulus Amebocyte Lysate Test for Gram-negative bacterial endotoxin (LAL QCL-1000, Basal, Switzerland) with a detection limit of 0.1 EU ml⁻¹. Samples were carefully processed for this assay using endotoxin-free consumables. Total IgM was measured using an ELISA test kit (Immunology Consultants Laboratory Inc., Portland, OR, USA).

Finally, endotoxin-core IgM and IgG antibodies (EndoCAB) were measured by ELISA as described elsewhere.^{21,22} In brief, polystyrene microplates were pre-coated with an equimolar mixture of incomplete-core rough mutant endotoxins from each of four species of Gram-negative bacteria, complexed with polymyxin B. An eight-point standard curve was constructed using doubling dilutions of a pooled serum calibrated in EndoCAB median units and was used on every plate. Test samples were diluted 1:200 with dilution buffer and 100 µl of each sample added in duplicate to the plate and incubated for 60 min at 37 °C. After washing four times with wash buffer, 100 µl of a diluted alkaline phosphatase-conjugated goat anti-human IgG or IgM (Ig heavy-chain specific) antibody was added to each well and the plate was incubated for a further 60 min at 37 °C. The washing step was then repeated four times and 100 µl of the substrate solution (1 mg ml⁻¹ disodium *p*-nitrophenylphosphate dissolved in 1 M diethanolamine buffer) was added to the plate wells. The plate was incubated in the dark for 35 min and the reaction was stopped with 500 µl per well of 2 M sodium hydroxide and read at 405 nm. Repeat blood samples were collected on participants in the lean and obese non-diabetic categories approximately 2 weeks after the initial study visit in order to assess the reliability of the endotoxin and endotoxin core antibody measurements.

Statistical analysis

Data were analysed using STATA 11 (Stata Corporation, College Station, TX, USA). All biochemistry variables had right-skewed distributions and

residuals that were not normally distributed and were therefore log-transformed for the analysis. Geometric means (95% confidence intervals) have been presented for the descriptive statistics of these variables. Impaired fasting glucose was defined as fasting glucose ≥6.1–6.9 mmol l⁻¹, whereas diabetes was defined as fasting glucose ≥7.0 mmol l⁻¹ in accordance with WHO recommendations.²³ Insulin sensitivity was assessed by the QUICKI index (calculated as 1/(insulin(log) + glucose(log))) as several insulin values were below 20 pM, the lower limit for which the Homeostasis Model Assessment was validated.²⁴ The EndoCAB values for IgG and IgM in the obese and obese diabetic groups were calculated as a percentage of the mean value for lean subjects. Thus, the lean group acted as a healthy control group and the values for the other two groups were normalised with respect to these controls; all EndoCAB values are expressed as percentage median units (PMUs) where the mean for lean individuals is 100 PMU or 100%.

Descriptive statistics have been presented for the study participants divided into the three recruitment groups: lean, obese, obese diabetic. Analysis of variance was used to assess the difference in markers of endotoxin and inflammation across the exposure groups. The association between obesity and diabetes status and the markers of endotoxin and inflammation was further assessed by using linear regression models first fitting obesity (yes/no) as the explanatory variable and then fitting both obesity and diabetes as binary variables to assess any independent effect.

RESULTS

In total, 93 women were recruited; mean BMI for the lean group was 20.8 kg m⁻², for the obese group it was 34.3 kg m⁻² and for the obese diabetic group it was 33.3 kg m⁻² (Table 1). Total and trunkal fat masses were over 2.5-fold higher in the obese and obese diabetic groups (total fat: 14.2, 39.5 and 37.8 kg; trunkal fat: 6.3, 20.0 and 19.1 kg). The majority of women (55%) had been born in the urban region and the median amount of time spent living there for individuals who had been born elsewhere was 25 years. All women in the obese diabetic group were receiving medication to treat their condition. There was a marginal difference in age between the three groups (analysis of variance, *F*: 2.89; *P*-value: 0.06, *df*: 2,88), with women in the lean group on average 3.6 years younger than women in the diabetic group. As would be expected, diabetes prevalence (defined as fasting glucose above 7.0 mmol l⁻¹) was very different between the three groups with no women in the lean group, one woman in the obese non-diabetic group and 70% of women in the diabetic group. For the nine individuals in the diabetic group who did not have frank diabetes, their mean fasting glucose was still elevated at 5.9 mmol l⁻¹ (s.d. 0.7). Some of the markers of socioeconomic status were different between the groups with a much higher proportion of women in both obese groups having completed at least primary school education compared with lean participants. Women in both obese categories also reported owning a larger number of assets and having greater access to a flush toilet compared with women in the lean category.

Mean endotoxin detected in plasma for the entire sample was 4.25 EU ml⁻¹ (95% confidence interval (CI): 3.65, 4.96). Repeat samples were conducted on 48 individuals and the correlation between the first and second measurements was poor at 0.2. Mean anti-endotoxin IgG antibody for the entire sample was 109.6 PMU (95% CI: 94.53, 127.0) and the correlation between repeat samples was 0.54. Mean anti-endotoxin IgM antibody for the entire sample was 55.45 PMU (95% CI: 46.54, 66.07) and the correlation between repeat samples was 0.82. The analysis presented focuses on samples obtained from the first study visit. Stool samples were more difficult to obtain than blood samples due to reluctance by some participants and a total of 72 samples were collected for the assessment of faecal calprotectin, representing 77% of participants. Mean calprotectin was 45.73 mg kg⁻¹ (95% CI: 34.42, 60.76). Mean IL-6 for the entire sample was 1.11 pg ml⁻¹ (95% CI: 0.92, 1.33).

Endotoxin levels were higher in the obese diabetic group compared with both the lean and obese non-diabetic groups

Table 1. Descriptive statistics of the study sample by BMI/diabetic group

| Variable | Mean (s.d.) or percentage ^a | | |
|---|--|---------------------|---------------------|
| | Lean (n: 31) | Obese (n: 33) | Diabetic (n: 29) |
| Age (year) | 41.5 (6.2) | 43.4 (5.4) | 45.1 (5.2) |
| Born in urban region (%) | 67.7 | 57.6 | 51.7 |
| Education (%) ^b | 9.1 (n = 22) | 38.5 (n = 26) | 31.3 (n = 29) |
| Water within the home (%) ^c | 63.3 | 71.9 | 75.0 |
| Flush toilet (%) ^d | 22.6 | 51.5 | 58.6 |
| Assets owned ^e | 4.2 (2.3) | 5.8 (1.9) | 6.7 (1.9) |
| Height (m) | 1.6 (0.1) | 1.6 (0.1) | 1.6 (0.1) |
| Weight (kg) | 55.0 (5.3) | 90.2 (13.2) | 87.2 (16.9) |
| BMI (kg m ⁻²) | 20.8 (1.8) | 34.3 (4.5) | 33.3 (5.7) |
| Fat mass (kg) ^f | 14.2 (4.0) | 39.5 (8.8) | 37.8 (11.3) |
| Trunk fat mass (kg) ^f | 6.3 (2.5) | 20.0 (4.6) | 19.1 (5.3) |
| Systolic BP (mm Hg) | 114.0 (14.1) | 126.6 (19.7) | 125.3 (17.1) |
| Diastolic BP (mm Hg) | 73.3 (8.8) | 84.0 (12.3) | 84.2 (9.3) |
| Hypertensive (%) ^g | 6.7 | 26.7 | 13.8 |
| Fasted glucose (mmol l ⁻¹) | 5.00 (4.84, 5.17) | 5.51 (5.23, 5.80) | 9.19 (7.75, 10.89) |
| Fasted insulin (pg ml ⁻¹) | 4.31 (3.28, 5.65) | 11.08 (9.08, 13.52) | 12.11 (9.71, 15.09) |
| QUICKI index ^h | 0.35 (0.08) | 0.25 (0.04) | 0.22 (0.03) |
| Impaired fasting glucose (%) ⁱ | 3.5 | 12.5 | 82.1 |
| Diabetes (%) ^j | 0 | 3.1 | 67.9 |

Abbreviations: BMI, body mass index; BP, blood pressure, CI, confidence interval. ^aGeometric means (95% CI) have been presented for skewed variables. ^bProportion of women who have completed at least primary school compared with those with no formal schooling or only an Arabic school education. ^cProportion of women who have a water source within their compound rather than using a public tap. ^dProportion of women who have a flush toilet compared with a pit latrine. ^eTotal number of assets owned by the household calculated from yes/no answers to the following: electricity, television, motorcycle, radio, bicycle, car, fridge, telephone, land, goats and chickens. ^fFat mass measured using the Tanita BC-418MA bioelectrical impedance analyser. ^gHypertension defined as systolic BP > 140 mm Hg. ^hInsulin sensitivity assessed by the QUICKI index calculated as QUICKI = 1/(log(Insulin) + log(glucose)) used as an estimate of insulin sensitivity. ⁱImpaired fasting glucose defined as fasting glucose ≥ 6.1 mmol l⁻¹. ^jDiabetes defined as fasting glucose ≥ 7.0 mmol l⁻¹.

Table 2. Distribution of inflammatory and endotoxin measurements by BMI/diabetic group

| Variable | Geometric mean (95% CI) or percentage | | | ANOVA/logistic regression ^a |
|--|---------------------------------------|------------------------|------------------------|--|
| | Lean (n: 31) | Obese (n: 33) | Diabetic (n: 29) | |
| Endotoxin (EU/ml) | 3.89 (3.20, 4.73) | 3.86 (3.30, 4.52) | 5.19 (3.43, 7.87) | F: 4.16 P: 0.02 |
| EndoCAB-IgG (PMU) ^b | 100.0 (71.71, 139.41) | 121.22 (95.10, 254.50) | 108.14 (88.72, 131.80) | F: 0.57 P: 0.57 |
| EndoCAB-IgM (PMU) ^b | 100.00 (80.46, 124.29) | 55.23 (41.51, 73.49) | 30.26 (23.26, 39.37) | F: 21.73 P: <0.001 |
| Total IgM (mg dl ⁻¹) | 65.79 (42.87, 100.97) | 70.01 (48.41, 101.26) | 69.79 (43.55, 111.85) | F: 0.03 P: 0.97 |
| Interleukin-6 (pg ml ⁻¹) | 0.60 (0.41, 0.88) | 1.23 (0.97, 1.55) | 1.92 (1.57, 2.35) | F: 12.68 P: <0.001 |
| Faecal calprotectin (mg kg ⁻¹) | 39.38 (24.04, 64.51) | 40.26 (23.61, 68.68) | 61.38 (37.25, 101.17) | F: 1.0 P: 0.37 |
| Raised calprotectin (%) ^c | 41.7 (21.2, 62.2) | 44.0 (23.8, 64.2) | 52.2 (30.9, 73.4) | OR: 1.24 P: 0.47 |

Abbreviations: ANOVA, analysis of variance; BMI, body mass index; CI, confidence interval; EndoCAB, endotoxin core antibody; OR, odds ratio, PMU, percentage median unit. ^aANOVA test conducted on log transformed variables to satisfy assumptions of normality. Individuals in the lean group coded 1, obese 2 and diabetic 3. Logistic regression conducted on the categorical calprotectin outcome. ^bEndotoxin-core antibodies (EndoCAB) were determined in 'median units' relative to a standard of healthy UK blood donors and normalised to the lean population where the mean is shown as 100 PMU ('percent median units'). ^cProportion of individuals with calprotectin levels above the normal threshold of 50 mg kg⁻¹.

(Table 2), and, as expected, IL-6 levels were raised by obesity and highest in the diabetic group. Anti-endotoxin IgG antibodies were not different between the three groups, and there was no difference in faecal calprotectin. Anti-endotoxin IgM antibodies showed a very strong reverse association; both the obese non-diabetic and obese diabetic groups had much lower levels than the lean comparison group (F-ratio for trend = 21.73, $P < 0.0001$). In contrast, there was no difference in total IgM between the three groups. Applying a Bonferroni correction ($\alpha = 0.01$) to account for multiple comparisons between groups still reveals a difference in anti-endotoxin IgM and IL-6 levels between the three groups.

Simple linear regression analysis for all groups combined showed a positive association between log fasting glucose and log endotoxin levels (β : 0.24 EU ml⁻¹, 95% CI: 0.09, 0.38; P : 0.001)

but not between log fasting insulin and log endotoxin (β : 0.20 EU ml⁻¹, 95% CI: -0.12, 0.51; P : 0.22). There was a negative association between log fasting glucose and log anti-endotoxin IgM antibodies (β : -0.16 PMU, 95% CI: -0.25, -0.07; P : <0.001) and between log fasting insulin and anti-endotoxin IgM (β : -0.24 PMU, 95% CI: -0.43, -0.06; P : 0.01). There was a positive association between QUICKI index and log anti-endotoxin IgM antibodies (β : 0.03 PMU, 95% CI: 0.01, 0.05; P : 0.01) but no association with either endotoxin or anti-endotoxin IgG antibodies (data not shown). There was also no association between anti-endotoxin IgG antibodies and either glucose or insulin (data not shown). There was a negative association between whole-body fat mass and log anti-endotoxin IgM antibodies (β : -5.86 PMU, 95% CI: -9.29, -2.44; P : 0.001) but no association between

Table 3. Association between endotoxin and inflammatory markers with obesity and diabetes separately

| Variable | Condition | Mean difference (95% CI) ^a | P-value |
|--|--------------------------|---------------------------------------|---------|
| Log endotoxin (EU ml ⁻¹) | Obesity | 0.14 (-0.08, 0.37) | 0.21 |
| | Obesity adj for diabetes | 0.001 (-0.24, 0.24) | 0.99 |
| | Diabetes adj for obesity | 0.43 (0.16, 0.70) | 0.002 |
| Log EndoCAB-IgG (PMU) ^b | Obesity | 0.14 (-0.18, 0.45) | 0.39 |
| | Obesity adj for diabetes | 0.19 (-0.16, 0.54) | 0.29 |
| | Diabetes adj for obesity | -0.07 (-0.46, 0.32) | 0.73 |
| Log EndoCAB-IgM (PMU) ^b | Obesity | -0.88 (-1.21, -0.55) | <0.001 |
| | Obesity adj for diabetes | -0.69 (-1.04, -0.34) | <0.001 |
| | Diabetes adj for obesity | -0.53 (-0.92, -0.14) | 0.01 |
| Log total IgM (mg dl ⁻¹) | Obesity | 0.06 (-0.44, 0.56) | 0.81 |
| | Obesity adj for diabetes | 0.17 (-0.39, 0.74) | 0.55 |
| | Diabetes adj for obesity | -0.27 (-0.89, 0.35) | 0.38 |
| Log faecal calprotectin (mg kg ⁻¹) | Obesity | 0.22 (-0.38, 0.83) | 0.46 |
| | Obesity adj for diabetes | 0.20 (-0.47, 0.86) | 0.56 |
| | Diabetes adj for obesity | 0.29 (-0.46, 1.03) | 0.45 |
| Log IL-6 (pg ml ⁻¹) | Obesity | 0.38 (0.21, 0.56) | <0.001 |
| | Obesity adj for diabetes | 0.31 (0.12, 0.51) | 0.002 |
| | Diabetes adj for obesity | 0.21 (-0.01, 0.43) | 0.06 |

Abbreviations: adj, adjusted; CI, confidence interval; EndoCAB, endotoxin core antibodies; PMU, percentage median unit. ^aEffect estimates from linear regression analysis. Obesity model includes obesity (coded 1,0) only. 'Obesity adj for diabetes' and 'Diabetes adj for obesity' includes both obesity and diabetes variables (coded 1,0) fitted to the same model to assess independent association. Mean difference refers to difference in independent variable for obese compared with lean individuals or for diabetic (defined as fasting plasma glucose >7.0 mmol l⁻¹) compared with non-diabetic individuals ^bEndoCAB were determined in 'median units' relative to a standard of healthy UK blood donors and normalised to the lean population where the mean is shown as 100 PMU.

fat mass and endotoxin or anti-endotoxin IgG antibodies (data not shown).

An adjusted regression analysis was conducted to investigate the independent effect of obesity and diabetes on endotoxin and inflammatory markers. The initial model included obesity only with the subsequent models fitting both obesity and diabetes variables to assess any independent association with the outcomes of interest (Table 3). For this analysis, only individuals with fasting plasma glucose >7.0 mmol l⁻¹ were defined as having type 2 diabetes rather than including all individuals recruited from the diabetic clinic. Endotoxin was associated only with diabetes, whereas anti-endotoxin IgM antibodies and IL-6 were associated independently with both obesity and diabetes. Fitting potential confounding variables to the models (age, education, assets owned and water or waste management) did not affect the results (data not shown).

DISCUSSION

This 'proof-of-principal' study reveals some of the strongest human evidence to date in support of the theory that gut microbiota-derived bacterial products may drive a chronic low-grade inflammation that predisposes to insulin resistance and diabetes.

The potential role of the gut microbiota in the development of obesity and associated metabolic complications is receiving increasing attention. Animal studies have allowed for experiments into the causal nature of this association. Germ-free mice are protected against the development of 'Western' diet-induced insulin resistance¹² and transplantation of gut microbiota from obese mice into germ-free animals results in greater adiposity than transplant from lean donors.¹³ Studies in humans have also suggested the presence of an obesity-predisposing gut microbiome that can be amended by weight loss.^{25,26} In addition to a potential role in increased energy harvest, the gut microbiota are suggested as an important source of obesity-associated inflammation; a recognised driver of the pathogenesis of metabolic disease such as type 2 diabetes.

Substantial epidemiological evidence supports the role of inflammation in the pathogenesis of obesity and type 2

diabetes.^{5,6} The mechanisms are not fully understood but one potential pathway is the inactivation of the insulin receptor due to the binding of inflammatory factors (such as TNF- α) with insulin receptor substrate.²⁷ Macrophage infiltration of adipose tissue is an important source of inflammation associated with obesity, however, the swift resolution of inflammation and insulin resistance following bariatric surgery in patients with type 2 diabetes requires an explanation and has suggested the existence of pathways operating independently of weight loss,^{28,29} with bacterial endotoxin emerging as a putative candidate. Endotoxin is a potent stimulator of inflammation through CD14-induced secretion of cytokines (for example, TNF- α , IL-1 and IL-6) by macrophages.¹⁸ In mouse models, antibiotic-induced changes to the gut microbiota have been shown to result in reduced endotoxemia and improvements in metabolic disorders including adipose tissue inflammation and macrophage infiltration.³⁰ In human studies, *ex-vivo* treatment of adipose tissue with LPS causes an increase in the secretion of inflammatory markers TNF- α and IL-6.³¹

Certain constituents of the diet also are known to stimulate the release of pro-inflammatory cytokines; meals with a high-fat content have been implicated as a trigger of post-prandial inflammation through the activation of NF- κ B.^{32,33} However, the mechanisms of high-fat-induced low-grade inflammation are unclear and may also suggest a link with the gut microbiota.³⁴ For example, single-meal intervention studies have indicated that certain food types (fat and glucose) lead to raised endotoxin as part of post-prandial inflammation.³⁵⁻³⁷ In mouse models, a high-fat diet has been shown to initiate ME and CD14 knock-out mice are resistant to these effects.⁹ LPS has been shown to be transported by chylomicrons further suggesting a mechanism through which the fat composition of the diet may impact on endotoxin levels.³⁴ Endotoxin concentration is also determined by the integrity of the gut barrier, which may also be affected by the diet; prebiotic-treated mice have improved intestinal integrity and correspondingly lower plasma LPS.³⁰

Endotoxin levels observed in the current study were similar to those in a cross-sectional study of patients attending hospital in Saudi Arabia, where mean levels for non-diabetics were 4.2 EU ml⁻¹ and for diabetics treated with insulin were

9.2 EU ml⁻¹.¹⁶ A separate study of diabetic subjects and BMI-matched controls reported a 76% higher endotoxin concentration among the diabetics.³¹ In the present study, both EndoCAB-IgG and -IgM antibodies were measured in addition to circulating endotoxin. EndoCAB-IgG levels were similar for the three groups. In contrast, EndoCAB-IgM levels were highly significantly lower in the obese and obese diabetic groups compared with their lean counterparts ($F = 21.7$, $P < 0.0001$). There was virtually no overlap in EndoCAB-IgM levels between the three groups. Total IgM antibodies remained similar across the groups demonstrating an EndoCAB-specific effect. Note that the strong correlation between repeat measures of EndoCAB IgM validates our choice of this as a more robust marker of chronic exposure than LPS levels, which may vary with day-to-day changes in dietary patterns and showed a very poor intra-subject reproducibility. The paradoxical reduction in EndoCAB IgM levels in the obese and obese diabetics were unexpected and are challenging to explain. We hypothesise that it could be caused by degradation of IgM-LPS complex that is constantly neutralising a persistent endotoxin leakage from the gut. This might also help to explain why there is no such trend in EndoCAB-IgG levels. In settings with high background antibody levels, repeated exposure to endotoxin may not necessarily stimulate a new IgG-mediated immune response if there is sufficient antibody to neutralise incoming LPS. Depletion of circulating EndoCAB levels as the LPS-antibody complex is cleared may erode IgM antibodies much faster than IgG antibodies, as only 20% of IgG is in circulation and will be supplemented from the 80% extravascular pool of IgG.³⁸ The relative kinetics of IgM and IgG EndoCAB in this context is currently unknown and should be explored in future studies. Alternatively, chronic exposure among the obese and diabetic obese patients may have induced antibody class switching or even immune tolerance. Although there was no evidence for increased EndoCAB-IgG, we did not measure IgG isotypes in this study. It remains possible that the chronically exposed individuals produce an IgG of higher affinity rather than simply larger quantities.

Faecal calprotectin has been validated as a marker of gut inflammation against endoscopic and histologic grading of disease, and excretion of indium-111-labelled neutrophils, in ulcerative colitis patients.²⁰ The lack of any trend in this study might reflect the fact that it is a marker for more severe gut inflammation than is required to elicit endotoxin translocation. Alternatively, lipid-chaperoned translocation of LPS (and/or other bacterial debris) might occur even in the absence of gut damage as suggested by studies of post-prandial inflammation in response to high-fat meals.^{31–36}

There are a number of strengths of the current study. The three groups are well matched for age and for urban living and were selected to ensure there is a large difference between the lean and obese phenotypes in terms of their adiposity. Standard techniques were used to assess the study outcomes with validated commercial ELISA kits for the assessment of IL-6, faecal calprotectin and total IgM and the end point chromogenic Limulus Amebocyte Lysate assay for the assessment of endotoxin. The assessment of endotoxin antibodies was conducted using an ELISA, originally developed for screening blood donors but which has also been used in other settings including screening blood donors for clinically useful antibodies for passive immunoprophylaxis³⁹ and demonstrated excellent sensitivity for assessing chronic exposure with a repeat measures correlation of 0.82 in samples collected a fortnight apart.

The major limitation of the current study is that so far we only have cross-sectional data and, hence, cannot infer causality. A further limitation is the lack of information on dietary intake. Future diet manipulation studies will be required to aid our understanding of the link between diet, obesity and the gut microbiota impacts on metabolic disease.

In conclusion, we have shown that in urban Gambian women type 2 diabetes is associated with convincing evidence of ME, presumably due to translocation of bacterial products originating in the gut. The paradoxical reduction in anti-endotoxin IgM antibodies tentatively suggests that constant immunosurveillance may be depleting the available neutralising antibody. The markedly lower levels in diabetics could indicate either a greater exposure (driven by an altered microbiota and/or a more leaky gut and/or altered diet) or an impaired ability to sustain neutralising defences. Whether this is a particular attribute of diabetes in a low-income setting, where a persistent 'environmental enteropathy' has long been recognised as a contributor to growth faltering in children,⁴⁰ remains to be tested. If these findings are replicated in other studies, and a causal pathway emerges between diet composition, the composition and behaviour of the microbiota, damage to gut integrity and translocation of inflammatory agonists that ultimately impair insulin signalling, then this would open new avenues for intervention.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by UK Medical Research Council core funding to the International Nutrition Group (MC-A760-SQX00). We thank Ebou Touray for his assistance in the field and Kerry Jones, Ebrima Danso and Bakary Darboe for their work in the laboratories in MRC Keneba and MRC Fajara, The Gambia.

REFERENCES

- 1 Venables MC, Jeukendrup AE. Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. *Diabetes Metab Res Rev* 2009; **25**(Suppl 1): S18–S23.
- 2 Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J Clin Invest* 2006; **116**: 1793–1801.
- 3 Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am J Physiol Endocrinol Metab* 2001; **280**: E745–E751.
- 4 Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. *Obes Res* 2001; **9**: 414–417.
- 5 Dandona P, Ajladi A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. *Trends Immunol* 2004; **25**: 4–7.
- 6 Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology* 2007; **132**: 2169–2180.
- 7 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ *et al*. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* 2003; **112**: 1821–1830.
- 8 Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. *Curr Pharm Des* 2009; **15**: 1546–1558.
- 9 Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D *et al*. Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* 2007; **56**: 1761–1772.
- 10 Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? *Diabetes Care* 2010; **33**: 2277–2284.
- 11 Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. *Annu Rev Nutr* 2011; **31**: 15–31.
- 12 Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc Natl Acad Sci USA* 2007; **104**: 979–984.
- 13 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; **444**: 1027–1031.
- 14 Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. *Science* 2005; **307**: 1915–1920.
- 15 Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. *Curr Opin Immunol* 1999; **11**: 19–22.
- 16 Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, da Silva NF, Sabico SL, Kumar S *et al*. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. *Cardiovasc Diabetol* 2009; **8**: 20.

- 17 Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC *et al*. Energy intake is associated with endotoxemia in apparently healthy men. *Am J Clin Nutr* 2008; **87**: 1219–1223.
- 18 Poxton IR. Antibodies to lipopolysaccharide. *J Immunol Methods* 1995; **186**: 1–15.
- 19 Barclay GR. Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. In Levin J *et al.* (eds). *Bacterial Endotoxins: Lipopolysaccharides from Genes to Therapy*. John Wiley & Sons Inc: New York, 1995.
- 20 Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. *Aliment Pharmacol Ther* 2002; **16**: 675–681.
- 21 Stephens RC, Fidler K, Wilson P, Barclay GR, Mythen MG, Dixon GL *et al*. Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children. *Intensive Care Med* 2006; **32**: 286–294.
- 22 Barclay GR, Scott BB, Wright IH, Rogers PN, Smith DG, Poxton IR. Changes in anti-endotoxin-IgG antibody and endotoxaemia in three cases of gram-negative septic shock. *Circ Shock* 1989; **29**: 93–106.
- 23 WHO and IDF. *Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation*. World Health Organization: Geneva, Switzerland, 2006.
- 24 Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G *et al*. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000; **85**: 2402–2410.
- 25 Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006; **444**: 1022–1023.
- 26 Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y *et al*. Human gut microbiota in obesity and after gastric bypass. *Proc Natl Acad Sci USA* 2009; **106**: 2365–2370.
- 27 Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α and obesity-induced insulin resistance. *Science* 1996; **271**: 665–668.
- 28 Sandoval D. Bariatric surgeries: beyond restriction and malabsorption. *Int J Obes* 2011; **35**(Suppl 3): S45–S49.
- 29 Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. *Annu Rev Med* 2010; **61**: 393–411.
- 30 Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM *et al*. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes* 2008; **57**: 1470–1481.
- 31 Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M *et al*. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. *Am J Physiol Endocrinol Metab* 2007; **292**: E740–E747.
- 32 Bellido C, Lopez-Miranda J, Blanco-Colio LM, Perez-Martinez P, Muriana FJ, Martin-Ventura JL *et al*. Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in peripheral blood mononuclear cells from healthy men. *Am J Clin Nutr* 2004; **80**: 1487–1491.
- 33 Magne J, Mariotti F, Fischer R, Mathe V, Tome D, Huneau JF. Early postprandial low-grade inflammation after high-fat meal in healthy rats: possible involvement of visceral adipose tissue. *J Nutr Biochem* 2010; **21**: 550–555.
- 34 Laugerette F, Vors C, Peretti N, Michalski MC. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. *Biochimie* 2011; **93**: 39–45.
- 35 Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM *et al*. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. *Diabetes Care* 2009; **32**: 2281–2287.
- 36 Deopurkar R, Ghanim H, Friedman J, Abuaysheh S, Sia CL, Mohanty P *et al*. Differential effects of cream, glucose, and orange juice on inflammation, endotoxin, and the expression of Toll-like receptor-4 and suppressor of cytokine signaling-3. *Diabetes Care* 2010; **33**: 991–997.
- 37 Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. *Am J Clin Nutr* 2007; **86**: 1286–1292.
- 38 Pirofsky B, Campbell S, Montanaro A. Individual patient variations in the kinetics of intravenous immune globulin administration. *J Clin Immunol* 1982; **2**: 75–145.
- 39 Kelly P, Shawa T, Mwanamakondo S, Soko R, Smith G, Barclay GR *et al*. Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial. *BMC Gastroenterol* 2010; **10**: 72.
- 40 Lunn PG. The impact of infection and nutrition on gut function and growth in childhood. *Proc Nutr Soc* 2000; **59**: 147–154.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>